Research demonstrates NECTIN4 amplification predicts response to therapies in metastatic cancer, suggesting clinical relevance.
Introduction & objectives:NECTIN4 amplification has emerged as a promising biomarker for predicting response to targeted anti-NECTIN4 therapies in metastatic urothelial carcinoma (mUC), triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC). The anti-NECTIN4 antibody-drug [for full text, please go to the a.m. URL]
No takes yet. Share an insight, caveat, or question.
Weiten et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: